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eqOBJECTIVES The aim of this report is to characterize the impact of balloon aortic valvuloplasty (BAV) in patients
not undergoing aortic valve replacement in the PARTNER (Placement of AoRtic TraNscathetER Valves) trial.
BACKGROUND The PARTNER trial is the only randomized trial with independently adjudicated data of inoperable
severe symptomatic aortic stenosis patients, allowing outcome analysis of unoperated-on patients.
METHODS Thedesign and initial results of thePARTNER trial (CohortB)were reportedpreviously. After excludingpatients
with pre-randomization BAV, we compared patients undergoing BAV within 30 days of randomization (BAV group) with
those not having BAV within 30 days of randomization (no BAV group) to characterize the use and impact of BAV.
RESULTS In the PARTNER Cohort B study, 179 inoperable patients were randomized to standard treatment including
39 patients (21.8%) who had undergone a BAV before randomization (previous BAV group). Of the 140 patients who
did not have BAV before enrollment in the study, 102 patients (73%) had BAV within 30 days of study randomization
(BAV group). Survival at 3 months was greater in the BAV group compared with the no BAV group (88.2%; 95% con-
ﬁdence interval [CI]: 82.0% to 94.5% vs. 73.0%; 95% CI: 58.8% to 87.4%). However, survival was similar at 6-month
follow-up (74.5%; 95% CI: 66.1% to 83.0% vs. 73.1%; 58.8% to 87.4%). There was improvement in quality of life
parameters when paired comparisons were made between baseline and 30 days and 6 months between the BAV and no
BAV groups, but this effect was lost at 12-month follow-up.
CONCLUSIONS BAV improves functional status and survival in the short term, but these beneﬁts are not sustained.
BAV for aortic stenosis patients who cannot undergo aortic valve replacement is a useful palliative therapy.
(THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894) (J Am Coll Cardiol Intv
2015;8:324–33) © 2015 by the American College of Cardiology Foundation.m the *Cleveland Clinic Foundation, Cleveland, Ohio; yIrvine, California; zEmory University School of Medicine, Atlanta,
orgia; xNorthShore University Health System, Evanston, Illinois; kSaint Luke’s Mid America Heart Institute, Kansas City,
ssouri; {Duke Clinical Research Institute, Durham, North Carolina; #Cedars-Sinai Medical Center, Los Angeles, California; **St.
ul’s Hospital/University of British Columbia, Vancouver, British Columbia, Canada; yyNew York–Presbyterian Hospital/Weill
rnell Medical Center, New York, New York; zzMedical City Dallas Hospital, Dallas, Texas; xxStanford University, Stanford,
lifornia; and the kkNew York–Presbyterian Hospital/Columbia University Medical Center, New York, New York. The PARTNER
al was funded by Edwards Lifesciences and the protocol was designed collaboratively by the sponsor and the steering com-
ttee. The current analysis was carried out under the auspices of the PARTNER Publications Ofﬁce by academic investigators at
study sites, by an independent biostatistician (Dr. Anderson), and by the Health Economics and Technology Assessment
oup at Saint Luke’s Mid America Heart Institute, Kansas City, Missouri (Dr. Cohen). Dr. Anderson is a consultant for and holds
uity in Edwards Lifesciences. Dr. Babaliaros is an investigator for the PARTNER trial (Edwards Lifesciences). Dr. Feldman has
AB BR E V I A T I O N S
AND ACRONYM S
AS = aortic stenosis
AVR = aortic valve
replacement
BAV = balloon aortic
valvuloplasty
CI = conﬁdence interval
NYHA = New York Heart
Association
QOL = quality of life
STS = Society of Thoracic
Surgeons
TAVR = transcatheter aortic
replacement
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325A ortic stenosis (AS) is a common conditionamong the elderly and is associated withpoor survival without surgery once symp-
toms develop (1,2). In addition, patients with severe
AS experience progressive symptoms with reduced
functional status and quality of life (QOL). Despite
the success of surgical valve replacement in allevi-
ating symptoms, improving functional status, and
extending survival (3,4), a substantial minority of pa-
tients with severe AS remain untreated due to
prohibitive surgical risk (5,6). One-year mortality
rates may exceed 50% in these patients (7).
After the ﬁrst human report in 2002 (8), trans-
catheter aortic valve replacement (TAVR) has
emerged as a less invasive treatment option for pa-
tients with AS and a high or unacceptable surgical risk
(9–11). The PARTNER (Placement of AoRtic TraNs-
cathetER Valves) trial demonstrated that for patients
who are not suitable candidates for surgery, TAVR led
to a 20% absolute reduction in all-cause mortality at
1 year compared with standard therapy, and this
beneﬁt was sustained and actually more pronounced
when patients were followed for 2 years (12). Beyond
its mortality beneﬁt, TAVR led to improvement in
symptoms, functional status, and QOL, which may be
more important than the survival beneﬁt for these
elderly patients (13).
The PARTNER trial was the ﬁrst randomized trial
with a collection of outcome adjudicated data on
inoperable patients, allowing one to study the out-
comes of unoperated-on patients with severe symp-
tomatic AS. Although balloon aortic valvuloplasty
(BAV) has been used for palliation as well as a bridge
to surgical aortic valve replacement (AVR), the impact
of BAV has not been studied with independent adju-
dication compared with standard medical therapy
(14–16). The standard therapy arm of the PARTNER
trial provides an opportunity to better understand the
role of BAV in inoperable patients. In this report, wereceived grant support from and consulting fees/honoraria from Abbott Va
Lifesciences. Dr. Cohen has received grant support from Abbott Vascular, Bos
Lilly/Daiichi-Sankyo, MedRad, Medtronic, and Merck/Schering-Plough; an
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Lifesciences related to their work as unpaid members of the PARTNER Trial E
that they have no relationships relevant to the contents of this paper to dis
Manuscript received March 19, 2014; revised manuscript received August 27attempt to characterize the outcomes of
standard therapy in patients not undergoing
TAVR with a special focus on the role of BAV.
METHODS
STUDY DESIGN. The design and initial re-
sults of the PARTNER trial (Cohort B) were
published previously (17). In brief, the
PARTNER program enrolled patients with
severe AS, New York Heart Association func-
tional class II, III, or IV heart failure symp-
toms, and prohibitively high surgical risk
based on the Society for Thoracic Surgeons
(STS) risk score and qualifying assessments
by the heart team. Patients included in the present
study were not considered to be suitable candidates
for cardiac surgery because of coexisting medical
conditions associated with a predicted probability of
death or permanent disability $50%, as determined
by at least 2 surgical investigators and reafﬁrmed by
the study’s executive committee. These patients were
then randomized to TAVR, using the Edwards SAPIEN
heart valve system (Edwards Lifesciences, Irvine,
California), or standard medical care, which often
included BAV at the discretion of the investigators.
There was no speciﬁc time stipulated in the protocol
for TAVR after randomization, although treatment
within 2 weeks of randomization was encouraged.
The PARTNER trial was funded by Edwards Life-
sciences and designed collaboratively by the steering
committee and the sponsor. The study was approved
by each participating site’s Institutional Review
Board, and all patients provided written informed
consent. All events were independently adjudicated,
and echocardiograms were interpreted by a core lab-
oratory. The current analysis was carried out by aca-
demic investigators at the study sites and by the
Health Economics and Technology Assessment Group
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326at Saint Luke’s Mid America Heart Institute (Kansas
City, Missouri). The authors had unrestricted access
to the study data, drafted the manuscript, and vouch
for the veracity and completeness of its content.
BAV USE AND IMPACT ON OUTCOMES. We compared
the characteristics of patients who had BAV before
randomization (previous BAV group) with those
who never had BAV. After excluding patients with
pre-randomization BAV, we compared patients un-
dergoing BAV within 30 days (BAV group) with
those not having BAV within 30 days of randomi-
zation (no BAV group) to characterize the use and
impact of BAV on these inoperable patients in the
study.
STATISTICAL ANALYSIS. A randomized sample size
of 350 patients was computed to obtain appropriatePatient Characteristics: Patients With and Without
re Randomization
aracteristics
All Patients
(N ¼ 179)
Previous BAV
(N ¼ 39)
No Previous BAV
(N ¼ 140)
83.2  8.3 83.6  7.5 83.1  8.5
46.9 35.9 50.0
11.8  4.8 11.9  3.8 11.8  5.1
uroSCORE 30.5  19.0 30.0  18.1 30.6  19.3
ctional class III or IV 93.9 92.3 94.3
74.3 74.4 74.3
I 26.3 15.4 29.3
ABG 40.8 33.3 42.9
CI 21.8 23.1 21.4
25.7 33.3 23.6
25.1 17.9 27.1
72.3 70.4 70.4
ndent 25.7 23.1 26.4
>2 mg/dl 9.6 7.9 9.3
llation 28.6 29.4 28.3
t pacemaker 17.3 25.6 15.0
HTN 43.8 52.0 41.7
28.0 32.0 26.9
aorta 11.2 5.1 12.9
l radiation 8.4 15.4 6.4
l deformity 5.0 5.1 5.0
se 3.4 5.1 5.0
ient, mm Hg 72.9  24.3 68.9  24.3 73.9  24.2
ient, mm Hg 43.1  15.2 40.6  14.8 43.7  15.3
0.6  0.2 0.7  0.2 0.6  0.2
action 51.3  14.2 92.3 94.3
rate to severe 23.5 74.4 74.3
ate to severe 15.6 15.4 29.3
ean  SD or %.
ic insufﬁciency; AVA ¼ aortic valve area; BAV ¼ balloon aortic valvuloplasty; CABG ¼
tery bypass graft; CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pul-
ase; CVD ¼ cerebrovascular disease; HTN ¼ hypertension; MI ¼myocardial infarction;
l regurgitation; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary
; PVD ¼ peripheral vascular disease; STS ¼ Society of Thoracic Surgeons.power for analyzing the primary trial endpoints; the
actual randomized enrollment was 179 in each trial
arm. The trial was not powered for the various sepa-
rate standard therapy analyses described in this
paper. BAV was among the options that could be
chosen for treatment in the standard therapy arm and
was performed at various post-randomization time
points. For purposes of presenting the effect of BAV,
patients were placed into 3 groups: BAV before the
trial, BAV during the trial, and no BAV. Because
assignment to these 3 groups was not randomized,
any comparisons are purely descriptive, and no for-
mal statistical comparisons among the 3 groups are
presented. The analysis was based on the October 9,
2012 data extract with analysis close date as of March
16, 2012. This close date was 3 years after the last
randomization. The time of each event was calculated
from the date of randomization. Deaths and other
adverse events occurring after the analysis close date
are not considered in the analysis. Categorical vari-
ables are presented as frequencies and compared with
the use of the Fisher exact test. Continuous variables
are presented as mean  SD and compared using the
t test or paired t tests as appropriate. Survival curves
for time-to-event variables were constructed on the
basis of all available follow-up data with the use of
Kaplan-Meier estimates; patients were censored at
the last date known alive or the analysis close date,
whichever came ﬁrst. To identify predictors of mor-
tality, covariate analysis was performed using the
Cox proportional hazards algorithm. All statistical
analyses were performed using SAS software, version
9.3 (SAS Institute, Cary, North Carolina).
Data were collected from all 17 clinical sites.
Various poolability analyses were presented to the
U.S. Food and Drug Administration, and after exten-
sive review, the U.S. Food and Drug Administration
accepted poolability of site results for the primary
endpoint and all the secondary endpoints. The Pre-
Market Approval was presented in this manner, and
all subsequent publications have also used pooled
site data; that practice has been followed in this
manuscript.
RESULTS
PATIENT POPULATION. In the PARTNER Cohort B
study, 179 inoperable patients were randomized to
standard treatment without TAVR. At the time of
enrollment, the majority of the patients were on
contemporary treatment for heart failure: diuretics,
80%; beta-blockers, 62%; statins, 61%; angiotensin-
converting enzyme inhibitor or angiotensin recep-
tor blocker, 41%; aspirin, 59%; and warfarin, 24%.
TABLE 2 Baseline Characteristics of Patients Who Did or Did Not
Undergo BAV Within 30 Days of Randomization (Excluding Those
Who Already Had BAV Before Randomization)
Characteristics
No BAV Group
(N ¼ 38)
BAV Group
(N ¼ 102)
Age, yrs 82.2  9.4 83.4  8.2
Male 47.4 51.0
STS score 11.3  6.0 12.0  4.7
Logistic EuroSCORE 21.9  13.4 33.8  20.2
NYHA functional class III or IV 86.8 97.1
CAD 68.4 76.5
Previous MI 36.8 26.5
Previous CABG 31.6 47.1
Previous PCI 18.4 22.5
CVD 21.1 24.5
PVD 26.3 27.5
COPD
Any 75 71.8
O2 dependent 31.6 24.5
Creatinine >2 mg/dl 10.5 8.8
Atrial ﬁbrillation 38.5 25.3
Permanent pacemaker 15.8 14.7
Pulmonary HTN 26.9 47.1
Frailty 8.0 33.8
Porcelain aorta 18.4 10.8
Chest wall radiation 7.9 5.9
Chest wall deformity 10.5 2.9
Liver disease 2.6 3.9
Peak gradient 68.6  20.3 76.0  25.4
Mean gradient 40.0  12.4 45.1  16.1
AVA 0.7  0.2 0.6  0.2
Ejection fraction 52.5  13.3 51.1  14.4
MR, moderate to severe 20.0 24.7
AI, moderate to severe 7.7 14.6
N ¼ 32 N ¼ 97
KCCQ Overall Summary Scale 36.92  23.24 33.25  17.62
KCCQ Total Symptom Scale 48.72  24.40 44.57  22.82
KCCQ Physical Limitation
Scale Score
31.47  26.42 31.03  24.83
KCCQ Social Limitation Scale 30.51  28.38 24.93  21.99
KCCQ Quality of Life Scale 34.72  21.34 30.29  20.81
SF-12 Physical Summary 27.72  6.71 27.28  6.92
SF-12 Mental Summary 44.13  10.62 44.20  10.83
EQ-5D Utility Weight 0.54  0.26 0.57  0.22
Values are mean  SD or %.
KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; other abbreviations as in
Table 1.
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327Despite aggressive medical treatment, 94% of pa-
tients were in New York Heart Association (NYHA)
functional class III or IV heart failure. Of these 179
patients, 39 (21.7%) had undergone BAV weeks to
months before enrolling in the PARTNER trial (me-
dian, 121 days). The previous BAV group of patients
had similar clinical and echocardiographic character-
istics compared with patients who did not have BAV
before enrollment (Table 1).
BAV USE. In the PARTNER trial, many centers used
BAV as the next treatment tool in severely symp-
tomatic patients who were already receiving optimal
medical treatment. Of the 22 centers that participated
in the PARTNER trial, 17 performed BAV in more than
50% of their patients who were randomized to stan-
dard therapy. Ten centers used it in more than 90%
of their patients.
Of the 140 patients who did not have BAV before
enrolling in the study, 102 patients were included
in the BAV group, with BAV performed within 30 days
of study randomization (median, 3 days). To under-
stand the impact of BAV, characteristics of the pa-
tients undergoing their ﬁrst BAV within 30 days of
randomization were compared with those of the 38
patients who did not undergo BAV within 30 days
of randomization (no BAV group) (Table 2). Patients
undergoing BAV had more severe congestive heart
failure symptoms and a higher logistic EuroSCORE.
However, other characteristics including STS score,
echocardiographic characteristics, and QOL parame-
ters were not different between these 2 groups. There
were 53 patients who had BAV past 30 days, and 12
of these had more than 1 such BAV.
HEMODYNAMIC RESPONSE TO BAV. The BAV group of
patients demonstrated improvement in gradients and
aortic valve area. Echocardiographic information was
available for 96 patients before and after BAV. After
the ﬁrst BAV, the mean aortic valve gradient deter-
mined by transthoracic echocardiography decreased
signiﬁcantly from 44.8  15.9 mm Hg to 31.5  12.1
mm Hg, and the aortic valve area increased signiﬁ-
cantly from 0.6  0.2 cm2 to 0.8  0.2 cm2.
In the BAV group of patients, a second BAV was
performed in 29 patients 282  158 days after the
ﬁrst BAV. Seven patients underwent a third BAV
after 201  144 days of the second BAV, 2 patients
had a fourth BAV after an interval of 163 days after
the third BAV. In contrast to the ﬁrst BAV, hemo-
dynamic improvement after the second BAV was
negligible; the change in mean gradient from 46.4 
18.7 mm Hg to 44.5  16.8 mm Hg was not sig-
niﬁcant, and aortic valve area was unchanged at
0.7  0.2 (Table 3).COMPLICATIONS OF BAV. After 189 BAV procedures
during the trial, 8 deaths occurred within 30 days
after the BAV (4.2%). Stroke occurred in 2 patients
(1.1%) during the same period. There was no change
in magnitude of aortic regurgitation (1.6  0.9þ vs 1.7
 0.9þ). Aortic regurgitation was none, trace, mild,
moderate, and severe in 14%, 31%, 57%, 11%, and 1%
of patients, respectively, and after the ﬁrst BAV, the
counts were 9%, 32%, 55%, 16%, and 2%, respectively.
TABLE 3 Echocardiographic Hemodynamic and Functional
Improvement After BAV
Pre Post Change p Value
First BAV (n ¼ 96)
Peak gradient, mm Hg 75.4  25.0 54.6  19.6 20.8  21.3 <.0001
Mean gradient, mm Hg 44.8  15.9 31.5  12.1 13.2  13.5 <.0001
AVA, cm2 0.6  0.2 0.8  0.2 0.2  0.3 <.0001
AI, 0–4þ 1.6  0.9 1.7  0.9 0.1  0.7 0.0469
MR, 0–4þ 1.8  0.9 1.7  1.0 0.1  0.8 0.3042
Walk distance, ft* 49.5  86.1 72.5  103.5 23.0  93.0 0.0317
Second BAV (n ¼ 18)
Peak gradient, mm Hg 78.7  30.8 73.3  24.6 5.4  13.3 0.1039
Mean gradient, mm Hg 46.4  18.7 44.5  16.8 1.9  6.7 0.2434
AVA, cm2 0.7  0.2 0.7  0.2 0.0  0.2 0.6033
AI, 0–4þ 1.9  0.8 1.9  0.8 0.1  0.6 0.7168
MR, 0–4þ 1.7  0.8 1.8  0.5 0.1  0.6 0.7168
Walk distance, ft† 129.1  103.1 91.3  100.8 37.8  99.3 0.2138
Values are mean  SD. *Data available for 78 patients. †Data available for 12 patients.
Abbreviations as in Table 1.
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328No crossovers to TAVR were allowed after BAV for
severe aortic regurgitation. All outcomes of the 3
groups of patients are reported in Table 4.
CLINICAL OUTCOMES. There was meaningful im-
provement in heart failure symptoms in the BAV
group compared with the no BAV group, as demon-
strated by improvement in NYHA functional class
(Figure 1). There was improvement in QOL parameters
when paired comparisons were made between base-
line and 30 days and 6 months in the BAV group, but
this effect was lost at 12-month follow-up (Table 5).
Survival at 3 months was higher in the BAV group
compared with the no BAV group (88.2%; 95% conﬁ-
dence interval [CI]: 82.0% to 94.5% vs. 73.0%; 95% CI:TABLE 4 Outcomes of Patients According to BAV Status
Outcome
30 Days 3 Mont
Previous BAV BAV No BAV Previous BAV B
Death 2.6 2.0 5.3 23.1 1
Cardiac death 2.6 0.0 5.3 18.7 10
Stroke 2.6 1.0 2.6 2.6
Major vascular 0.0 2.0 0.0 0.0
Major bleeding 0.0 5.9 2.7 2.6
Renal 0.0 2.0 2.7 2.6
New pacemaker 2.6 6.9 2.9 5.2
Endocarditis 0.0 0.0 0.0 0.0 0
MI 0.0 0.0 0.0 0.0 0
Rehospitalization 10.5 12.8 2.9 35.0 2
NYHA (survivors: functional
class I/II)
32.4 36.2 25.0 NA N
Values are %.
NA ¼ not available; other abbreviations as in Table 1.58.8% to 87.4%). However, survival was similar at
6 months follow up (74.5%; 95% CI: 66.1% to 83.0%
vs. 73.1%; 58.8% to 87.4%) (Figure 2). Of the 179 pa-
tients randomized to standard treatment, 135 patients
died during the trial; the cause of death was cardio-
vascular in 69, noncardiovascular in 21, and unknown
in 45 patients. At 3 months, there were fewer car-
diovascular deaths in the BAV group (Figure 2B).
Table 6 lists the univariate predictors of mortality
in the unoperated-on severe symptomatic AS pa-
tients. Previous stroke or transient ischemic attack
and a history of pacemaker implantation were the
most important predictors of mortality. Interestingly,
patients who underwent BAV before enrolling in the
PARTNER trial had a higher mortality rate. The STS
risk score was a signiﬁcant predictor of mortality.
Patients with an STS score <10 had better survival
than those with an STS score of 10 to 15 or more than
15 (Figure 3).
In 11 of the 179 patients (6.1%), overall clinical
status improved to the point that the decision of
inoperability was reconsidered, and they underwent
surgical AVR. Of the 39 patients who did not undergo
BAV, only 1 (2.5%) underwent AVR. Fifty percent
(5 of 10 with 1 unknown) of the patients undergoing
surgery survived to 1 year after surgery.
DISCUSSION
There are several major observations that can be
made from the detailed analysis of these prospec-
tively collected data. First, the outcome of patients
with severe symptomatic AS who do not undergo AVR
is poor. Second, BAV improves outcomes in these
inoperable patients for a few months. Third, repeat
valvuloplasties are less effective than the ﬁrst one.hs 6 Months 1 Year
AV No BAV Previous BAV BAV No BAV Previous BAV BAV No BAV
1.8 26.9 43.6 25.5 26.9 64.1 47.3 45.2
.0 26.9 40.4 21.3 26.9 57.3 40.6 42.3
2.1 5.9 2.6 4.6 5.9 2.6 6.2 5.9
2.0 3.6 0.0 2.0 3.6 6.3 2.0 3.6
5.9 9.3 9.8 8.3 13.1 15.4 15.6 13.1
3.1 2.7 5.9 3.1 2.7 5.9 4.9 2.7
7.9 2.9 8.6 9.1 2.9 8.6 10.5 2.9
.0 0.0 0.0 1.2 0.0 0.0 1.2 0.0
.0 3.7 0.0 0.0 3.7 0.0 0.0 3.7
1.3 18.9 55.5 33.5 29.9 75.0 51.7 39.0
A NA 19.0 40.3 28.6 36.4 33.3 58.8
FIGURE 1 New York Heart Association Functional Class
New York Heart Association functional class of patients in the balloon aortic valvuloplasty (BAV) group (n ¼ 102) compared with the no BAV
group (n ¼ 38) or previous BAV group (n ¼ 39).
TABLE 5 Change in Quality of Life Between Baseline and Follow-Up Time Points (Paired Data)
Group
30 Days 6 Months 12 Months
n Mean p Value n Mean p Value n Mean p Value
KCCQOS BAV 80 13.57 <0.0001 53 14.12 0.0003 41 1.60 0.7063
No BAV 21 1.16 0.7173 17 8.30 0.185 13 8.74 0.0296
KCCQTS BAV 80 13.27 <0.0001 52 10.88 0.0042 41 1.04 0.8049
No BAV 21 1.77 0.6725 17 4.53 0.4491 12 9.90 0.1053
KCCQPL BAV 62 9.51 0.0072 46 9.14 0.0282 34 2.72 0.594
No BAV 19 2.15 0.6463 16 9.22 0.1854 12 2.95 0.6341
KCCQSL BAV 67 12.22 0.0054 44 14.54 0.0068 37 2.53 0.6498
No BAV 19 1.32 0.7631 14 8.93 0.4289 10 7.29 0.309
KCCQQL BAV 79 18.94 <0.0001 52 20.83 <0.0001 41 5.18 0.314
No BAV 21 5.36 0.2609 17 12.26 0.101 12 14.24 0.0201
SF-12 PCS BAV 69 2.26 0.0234 46 3.76 0.0187 37 2.33 0.1755
No BAV 17 0.85 0.5498 15 1.03 0.6091 11 1.14 0.6685
SF-12 MCS BAV 69 3.47 0.0161 46 2.36 0.201 37 0.68 0.7419
No BAV 17 0.83 0.6783 15 3.82 0.1902 11 3.55 0.1487
BAV ¼ balloon aortic valvuloplasty; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; KCCQOS ¼ KCCQ Overall Summary Scale; KCCQPL¼ KCCQ Physical Limitation Scale
Score; KCCQQL¼ KCCQ Quality of Life Scale; KCCQSL¼ KCCQ Social Limitation Scale; KCCQTS ¼ KCCQ Total Symptom Scale; SF-12 MCS ¼ SF-12 Mental Summary;
SF-12 PCS ¼ SF-12 Physical Summary.
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FIGURE 2 Mortality and Cardiovascular Mortality
(A) All-cause mortality of patients undergoing balloon aortic valvuloplasty (BAV) within 30
days (n ¼ 102) compared with those not undergoing BAV (n ¼ 38) or undergoing BAV
before randomization (n ¼ 39). (B) Cardiovascular mortality of patients undergoing BAV
within 30 days (n ¼ 102) compared with those not undergoing BAV (n ¼ 38) or undergoing
BAV before randomization (n ¼ 39).
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330Fourth, the risk of BAV is not trivial but is in an
acceptable range. Fifth, major comorbidities respon-
sible for a high STS score predict mortality, even in
patients not undergoing AVR.
In 1933, Grant (18) reported 10-year follow-up of
43 male war prisoners with AS with or without
symptoms for 10 years. At the end of this follow-up,
28 had died; 10 died of cardiac failure, 7 of sudden
cardiac death, 2 of subacute bacterial endocarditis,
and 8 of unrelated causes. Harken et al. (19) reported
that 49 of 54 patients with AS (91%) who were advised
to have cardiac surgery and refused were dead within
6 months. Ross and Braunwald (1) reported in their
classic paper “recently, we have obtained follow-up
information on patients with isolated aortic valve
stenosis who were studied hemodynamically at the
National Heart Institute and in whom operation wasrefused or not carried out for a variety of reasons. Ten
of 12 patients with severe aortic stenosis (trans-
valvular pressure gradients $ 50 mm Hg, or effective
aortic valve oriﬁces #0.70 cm2/m2 BSA) who were
followed for at least ﬁve years after catheterization
are now dead.” Subsequently, they reported data
from 15 patients with severe well-characterized AS
and without aortic surgery with a 52% mortality
rate at 5 years, but these patients were young (32 to
59 years of age) (20,21). In 1991, O’Neill (22) reported
data from Mansﬁeld Scientiﬁc Aortic Balloon Valvu-
loplasty Registry for 492 patients with a 1-year sur-
vival rate of 64%, which is somewhat better than the
standard therapy arm of the PARTNER study (22,23).
However, the patient population was quite different,
with only 30% of patients refused by consulting car-
diovascular surgeons. The PARTNER trial population
is older (84 years of age vs. 79 years of age in the
Mansﬁeld Registry). The inoperability in the PART-
NER trial was determined by local surgeons and
conﬁrmed in a conference call by nationally recog-
nized expert aortic surgeons. This process ensured
a selection of inoperable patients who had more
comorbidities compared with the Mansﬁeld Registry.
Vascular complication rates were higher in the
Mansﬁeld Registry, probably related to the unavail-
ability of vascular closure devices. Very similar
data were reported from the National Heart, Lung,
and Blood Institute balloon valvuloplasty registry
around a similar time frame from a patient popula-
tion comparable to the Mansﬁeld Registry (24). A
well-characterized patient population, long-term
follow-up, and adjudicated event monitoring from
a contemporary era make the present paper unique.
Our study may be the ﬁrst, and possibly the
last, study in which inoperable high-risk medically
managed patients with AS were carefully studied
without aortic replacement in a randomized fashion.
There are many similarities of these data with those
of the studies done 80 and 45 years ago. However,
Ross and Braunwald studied the natural history of
AS in operable and young patients. It appears that
there has been no signiﬁcant improvement in the
medical treatment of severe AS in a century.
The prospectively collected data from unoperated-
on symptomatic AS patients in the PARTNER trial
will serve as a benchmark for future trials testing
new interventions. Although BAV was studied care-
fully in a multicenter registry in the 1990s and in
many other reports since then, these reports did not
use core laboratories for data collection and analysis,
and patient selection was not deﬁned. Our study of-
fers an opportunity to evaluate the contemporary
state of this procedure in a well-characterized and
FIGURE 3 Mortality Stratiﬁed by STS Score
Mortality of patients undergoing BAV within 30 days of randomization (n ¼ 102) according
to the Society of Thoracic Surgeons (STS) score (STS score >15, n ¼ 23; STS score <10,
n ¼ 29; 10 # STS # 15, n ¼ 60).
TABLE 6 Univariate Predictors of Mortality*
Predictor Hazard Ratio
95% Conﬁdence
Interval p Value
Stroke or TIA within past
6–12 months
4.141 1.281–13.39 0.0176
Previous pacemaker
implantation
2.039 1.357–3.064 0.0006
NYHA functional class 1.608 1.208–2.142 0.0011
LVEF <35% 1.593 1.032–2.457 0.0354
Atrial ﬁbrillation on
enrollment ECG
1.557 1.039–2.331 0.0317
Previous aortic valvuloplasty 1.553 1.051–2.295 0.0272
History of arrhythmia 1.539 1.091–2.172 0.0141
STS score >11 1.504 1.059–2.135 0.0227
STS risk score 1.039 1.003–1.075 0.0321
Baseline ejection fraction 0.987 0.975–0.999 0.0317
*The hazard analysis is based on all available follow-up data for each patient.
ECG ¼ electrocardiogram; LVEF ¼ left ventricular ejection fraction; TIA ¼
transient ischemic attack.
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331carefully selected group of patients. The rigor of data
collection, uniformity of deﬁnitions, and the pres-
ence of an independent clinical events committee
and an independent echocardiographic core labora-
tory make this analysis unique.
BAV is performed mainly to bridge high-risk
patients to surgical AVR or transcatheter AVR in
clinical practice. Reasons for bridging include tem-
porary contraindications to valve replacement (e.g.,
sepsis, severe debilitation, acute neurological event,
coagulopathy), other signiﬁcant cardiac lesions (cor-
onary, mitral valve, tricuspid valve, myocardial dis-
ease) where the relative contribution of AS to heart
failure remains questionable, or in patients with se-
vere noncardiac comorbidities in whom the role of
AS in presenting symptoms is difﬁcult to determine
(e.g., severe lung disease, cirrhosis, severe debilita-
tion). Infrequently, BAV can be used for patients with
symptomatic severe AS who require urgent major
noncardiac surgery. It can be helpful for palliation
in adult patients with AS in whom AVR cannot be
performed because of serious comorbid conditions,
although short-lived improvement makes such an
effort only a temporary success. This application of
BAV may be helpful to relieve extreme symptoms or
facilitate discharge of patients who are hospital
bound. Studies in the past have shown that although
BAV may result in temporary relief of symptoms,
restenosis is virtually certain within 6 to 12 months
(22,25–27). This led to the guidelines recommending
BAV as a reasonable bridge to surgery in hemody-
namically unstable patients at high risk of AVR or as a
palliative procedure in patients with AS at high risk of
surgical AVR (Class IIb indication) (28). This analysis
from the PARTNER trial highlights important facts
that are very relevant in clinical practice. There ap-
pears to be survival beneﬁt in patients undergoing
BAV in the ﬁrst 3 months. Therefore, one could argue
that if patients are not able to undergo AVR due to
temporary contraindications such as infection and
debility, there may be a survival beneﬁt of a strategy
with BAV as a bridge to deﬁnitive therapy. There is
evidence of a high mortality rate in patients being
screened for TAVR, representing a potential need for
such considerations (29,30). Because the mortality
matches patients not undergoing BAV at 6 months,
the data conﬁrm the need for deﬁnitive therapy (i.e.,
AVR or TAVR sooner rather than later after BAV).
Importantly, this analysis shows improvement in
QOL that persists for w6 months after BAV. Although
improvement in heart failure symptoms has been
reported with BAV, QOL improvement is important
additional data. The distinction between previously
reported functional improvement data and healthstatus measures reported here is an important one.
In this population, patient-reported QOL (based on
the Kansas City Cardiomyopathy Questionnaire and
SF-12) are used, whereas most other studies have
relied on external assessment (NYHA functional
class). This further substantiates the use of BAV as
a palliative therapy.
These data also provide some insight beyond
balloon valvuloplasty in these inoperable patients. A
few patients randomized to standard therapy did
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332undergo surgery, and they had poor outcomes, espe-
cially compared with those randomized to undergo
TAVR in whom the 1-year mortality rate was 31% (17).
Patients who underwent apico-descending aorta
conduit or surgical AVR had poor outcomes, with 33%
and 27% mortality rates in the ﬁrst 30 days,
respectively.
There are several implications of this analysis for
clinical practice. BAV can improve symptoms and
QOL, although early bridging to AVR is essential for a
better outcome. QOL can be improved to some extent
with BAV for w6-month duration.
STUDY LIMITATIONS. There are some limitations of
this analysis. Although the clinical characteristics of
patients who did and did not undergo BAV are
similar, selection bias in the decision regarding when
to perform BAV cannot be characterized. The patients
in this cohort were all candidates for TAVR, so the
results cannot be extrapolated to patients who were
excluded from the trial or so-called Cohort C patients.
Detailed procedural data on BAV were not
collected in these patients, and therefore procedural
variables could not be studied. Catheterization data
are limited, including pre- and post-valvuloplasty
data. Predictors of mortality could not be studied
in a time variant model due to the small number ofpatients. Further, clinical characteristics of patients
before repeat BAV were not collected in the trial.
Because the crossovers were not allowed until the
primary endpoint (1 year), patients who needed relief
of AS for survival underwent repeat BAV at the
discretion of the treating physician.
CONCLUSIONS
At 1 year, the survival of patients with inoperable
severe AS was 49.3%, with only 28.4% patients
without hospitalization and only 21% of the patients
in NYHA functional class I or II. Although BAV was
used in 84% of these patients, it was performed at the
discretion of physicians taking care of the patients,
and there was no survival beneﬁt at 1 year, patients
undergoing BAV in the trial had better 3-month sur-
vival and better 6-month QOL compared with pa-
tients not undergoing BAV in the trial. Standard
therapy for AS in patients who cannot undergo sur-
gery is inadequate. BAV for some patients who cannot
undergo AVR is a useful palliative therapy.
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